Astria Therapeutics (NASDAQ:ATXS) Trading Down 4.1% – What’s Next?

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s share price was down 4.1% on Monday . The stock traded as low as $11.14 and last traded at $11.14. Approximately 60,917 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 662,459 shares. The stock had previously closed at $11.62.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ATXS shares. Wedbush reissued an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. TD Cowen initiated coverage on Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 price target on the stock. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Oppenheimer increased their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a report on Tuesday, August 13th. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Friday, September 27th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Astria Therapeutics currently has an average rating of “Buy” and a consensus price target of $25.20.

Astria Therapeutics Price Performance

The firm has a market cap of $634.79 million, a price-to-earnings ratio of -4.95 and a beta of 0.71. The business has a 50-day moving average of $11.35 and a 200-day moving average of $10.50.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). As a group, equities analysts anticipate that Astria Therapeutics, Inc. will post -1.72 EPS for the current fiscal year.

Institutional Trading of Astria Therapeutics

A number of large investors have recently added to or reduced their stakes in ATXS. Rhumbline Advisers raised its holdings in shares of Astria Therapeutics by 4.1% in the 2nd quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock valued at $595,000 after purchasing an additional 2,556 shares during the period. Ameritas Investment Partners Inc. increased its position in Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after buying an additional 2,861 shares during the last quarter. Quest Partners LLC raised its stake in Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 3,112 shares during the period. American International Group Inc. lifted its position in shares of Astria Therapeutics by 49.4% in the first quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock valued at $346,000 after buying an additional 8,122 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Astria Therapeutics by 6.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock worth $1,266,000 after acquiring an additional 8,965 shares during the period. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.